In the CTRL-ROY group, enrichment was significant for “leukemia” and “acute leukemia” terms (NES = 2.12, Q = 0.03), driven by key myeloid malignancy-associated genes DNMT3A, IDH1, SRSF2, and TET2. This evidence concerns the gene SRSF2 and acute leukemia.